Beckman Coulter, Inc. (NYSE: BEC), a leading developer, manufacturer and marketer of products that simplify, automate and innovate complex biomedical testing, announced today first quarter ended March 31, 2010 results. Reported first quarter revenue, including $115.7 million from the recent Olympus Diagnostics acquisition (Olympus), was $881.1 million, up 27.4% over prior year quarter, or 23.6% in constant currency.

Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostic tests, announces the publication of a study showing microRNA expression differentiates between primary lung tumors and metastases to the lung. The study, entitled, “MicroRNA expression differentiates between primary lung tumors and metastases to the lung,” was published in the online edition of Pathology Research and Practice on April 28, 2010.

Gen-Probe Incorporated (Nasdaq: GPRO) today reported financial results for the first quarter of 2010, highlighted by $135.4 million of total revenues and earnings per share (EPS) of $0.48 on both a non-GAAP and GAAP basis.

LifeCodexx AG (www.lifecodexx.com ) has started operational research and development work on clinically validated diagnostic tests by using Next Generation Sequencing technologies. The work currently focuses on the field of prenatal diagnostics. LifeCodexx will utilize GATC Biotech’s 20 years of experience as well as its sequencing laboratory, which is the European leader with a total capacity of more than 2 terabases per year.

Illumina, Inc. (NASDAQ:ILMN) today announced shipment of HiScanSQ, the first instrument to integrate microarray analysis and next-generation sequencing in a modular design that can evolve with changing research needs. HiScanSQ is designed for smaller core labs that don’t want to purchase separate platforms to run sequencing and microarray experiments; groups that primarily run arrays but are looking to move into sequencing for the first time; and facilities that run both arrays and capillary electrophoresis sequencing and are looking to add high-throughput sequencing.

Eppendorf North America and Akonni Biosystems today announced they have entered into a joint marketing agreement to promote Akonni TruTip nucleic acid extraction kits configured for use with Eppendorf epMotion automated pipetting systems. Under the agreement, Eppendorf will promote the extraction kits to clinical, clinical research and forensic laboratories in North America – providing users with access to the industry’s most rapid and reliable means to automatically extract PCR-ready DNA and/or RNA from larger volume samples.

Affymetrix, Inc. (NASDAQ:AFFX) today announced the launch of the Axiom(TM) Genome-Wide ASI Array, the first commercial product to provide maximum power for genome-wide association studies (GWAS) in East Asian populations. This array is the second catalog release for the Axiom(TM) Genotyping Solution, which includes a suite of population-optimized arrays for genomic studies that will be delivered in the next year.

Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company has entered into an exclusive agreement with Palex Medical S.A., one of Europe’s leading distributors of medical device and diagnostic services to hospitals, to distribute its Oncotype DX(R) breast cancer test in Spain and Portugal. The distribution agreement, announced in conjunction with positive data presented today at the 7th European Breast Cancer Conference (EBCC), further expands the global presence of Oncotype DX, providing for increased physician and patient access to this advanced diagnostic test in the European market.

Sequenom, Inc. (Nasdaq: SQNM) today announced the launch of its next-generation mass spectrometry system - the MassARRAY(R) Analyzer 4. This new high performance nucleic acid analysis platform has been designed to meet customer demand for a bench top instrument with greater flexibility across multiple applications, improved reliability and faster performance. With the capability for quantitative gene expression analysis, epigenetic nucleic acid methylation analysis as well as high-throughput genotyping and SNP fine mapping applications, the MassARRAY Analyzer 4 is designed to empower the basic and translational research community to advance findings from basic genetic and biomarker studies toward clinical utility in diagnosis, prognosis and monitoring of diseases.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced today that it has acquired Proxeon A/S, an innovative supplier of products for proteomics analysis headquartered in Odense, Denmark. The company is recognized for its ability to provide a simplified proteomics workflow, including nanoflow liquid chromatography systems, columns, ion sources, and bioinformatics software, to meet the need for robust high-sensitivity liquid chromatography/mass spectrometry (LC/MS) analysis in complex proteomics applications. Proxeon had revenues of approximately $10 million in 2009 and has nearly 40 employees.

Affymetrix, Inc. (NASDAQ:AFFX) today announced the launch of the Affymetrix(R) MIP Copy Number Service, designed for cancer researchers using challenging FFPE samples. With the MIP Copy Number Service, scientists can now obtain high-quality allele-specific copy number data from FFPE samples. The service is available for research use only exclusively through the Affymetrix(R) Research Services Laboratory (ARSL).

Corporation (NYSE:MIL), a leading provider of technologies, tools and services for the global life science industry, today announced that it will disclose its financial results for the first quarter on Thursday, May 6, 2010, after the close of the stock market. The Company will webcast a conference call that evening to discuss its financial results, business outlook, and related corporate and financial matters. The call will begin at 4:45 p.m. Eastern Time and can be accessed through Millipore’s website at www.millipore.com.

Illumina, Inc. (NASDAQ:ILMN) today announced that it has sequenced the DNA of John, Judy, Anne and Paul West, the first publicly named family to have their DNA sequenced to full coverage by the company. The service was completed in Illumina’s CLIA certified and CAP accredited laboratory utilizing Illumina’s Genome Analyzer technology and following the established process shown at http://www.everygenome.com/.

Luminex Corporation (Nasdaq: LMNX) today announced that it expects to report results for the first quarter of 2010 on Thursday, May 6, 2010. A press release announcing the results is scheduled for release after the close of trading.

Epigenomics AG (Frankfurt Prime Standard: ECX), a cancer molecular diagnostics company, today hosted its Annual Press Conference and Analyst Meeting in Frankfurt/ Main. Geert Nygaard, CEO, and Oliver Schacht, CFO, informed on the results of the fiscal year 2009, reported on key highlights and provided an outlook on the company’s business activities and expectations for 2010 and beyond.